Opendata, web and dolomites

EHT-CaMKII

CaMKII over stimulation in engineered heart tissues (EHTs) made from human induced pluripotent stem cells (hiPSCs): a parameter involved in the immaturity of hiPSC EHTs cardiomyocytes?

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EHT-CaMKII project word cloud

Explore the words cloud of the EHT-CaMKII project. It provides you a very rough idea of what is the project "EHT-CaMKII" about.

artificial    despite    progression    3d    progressive    yes    functional    infarction    host    billion    context    hf    mortality    world    union    2d    biology    slow    drug    therapy    myocardial    function    indices    encompassing    parts    progress    tissues    last    normal    adult    myocardium    euros    clear    pathologies    combination    drugs    reduce    ischemic    cardiovascular    enhancement    eht    amount    human    consequently    deaths    death    preliminary    revert    isolated    isoforms    injured    ehts    modeling    successfully    restore    matching    interesting    200    treatment    advantages    cardiomyocytes    repair    camkii    treat    1994    phenotype    replace    malformed    cardiac    million    pluripotent    clinical    screening    suggest    contractile    cm    technique    hipscs    hipsc    stem    living    cells    heart    curative    biological    engineering    cms    cultured    syndrome    mature    maturation    laboratory    diseases    cv    disease   

Project "EHT-CaMKII" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF 

Organization address
address: Martinistrasse 52
city: HAMBURG
postcode: 20251
website: www.uke.uni-hamburg.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website https://www.uke.de/english/departments-institutes/institutes/experimental-pharmacology-and-toxicology/research/index.html
 Total cost 159˙460 €
 EC max contribution 159˙460 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2015
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2016
 Duration (year-month-day) from 2016-04-01   to  2018-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF DE (HAMBURG) coordinator 159˙460.00

Map

 Project objective

In Europe, as observed in other parts of the world, cardiovascular (CV) diseases represent the leading cause of death. In the European Union, CV deaths account for 1.9 million deaths per year, and treatment costs for CV disease amount to an estimated 200 billion Euros per year. CV diseases encompass various pathologies that can lead to a progressive loss of cardiac contractile function and the clinical syndrome of heart failure (HF), including ischemic heart disease and myocardial infarction. Drug therapy can successfully slow down the progression of HF and reduce mortality, but it cannot revert the loss of myocardium and thus provide no curative approach.

The engineering of 3D heart tissues (EHTs) has been developed in 1994 and, in combination with the recent availability of human induced pluripotent stem cells (hiPSCs), may represent a novel, promising technique to treat such cardiac pathologies. EHTs are artificial living and functional 3D heart tissues that could replace injured or malformed heart and restore normal cardiac function on the one hand, and help modeling cardiac diseases and testing drugs in a human heart context on the other hand. However, despite the last years progress and clear advantages compared to 2D cultured hiPSC-cardiomyocytes (CM), EHT-CMs do not reach a fully mature phenotype matching that of isolated CMs from the adult human heart.

Based on preliminary results obtained in the host laboratory, a set of indices suggest a role of CaMKII in the EHT-CMs maturation process. The objective of this proposal is thus to determine whether and, if yes, to which extent different CaMKII isoforms are involved in EHT-CM maturation. The EHT-CaMKII project could have very interesting impact on the EHT-CM maturation enhancement and, consequently, on numerous EHT applications encompassing cardiac repair, drug screening or disease modeling. In addition, it will contribute to understanding the biological role of CaMKII in CM biology.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EHT-CAMKII" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EHT-CAMKII" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

EVOMET (2019)

The rise and fall of metastatic clones under immune attack

Read More  

RegulatioNFkB (2019)

Deciphering transcriptional regulation of NF-kB target genes using integrative omics approaches

Read More  

ASIQS (2019)

Antiferromagnetic spintronics investigated by quantum sensing techniques

Read More